Gujarat Alkalies & Chemicals Ltd
Gujarat Alkalies & Chemicals Q3 FY26 investor presentation: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Net External Sales Value for Q3 2025-26 (YTD Dec 25) reported at Rs. EBITDA (Q3 FY 2025-26): ₹393.55 crores - Year-on-year: Up from ₹226.10 crores in Q3 FY 2024-25 - Operating Margin (EBITDA % of Total Income, Q3 FY 2025-26): 11.81% - Compared to 5.80%
From Gujarat Alkalies & Chemicals Ltd's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Net External Sales Value for Q3 2025-26 (YTD Dec 25) reported at Rs. 3,144.48 Crores, down from Rs. 3,959.50 Crores in 2024-25, indicating a year-on-year decline.
- Capacity utilization (%) by major product lines in Q3 2025-26: Caustic Soda Group 47%, Phosphoric Acid-Food & Technical Grade 15%, Chloromethanes 9%, Caustic Potash Group 5%, Hydrogen Peroxide 9%.
- No explicit forward-looking revenue or volume outlook is stated. The presentation emphasizes growth targets tied to Project Ahvaan: aspiration to reach revenue of ₹10,000+ Crores and EBITDA of 20%+ by FY 2031.
- New initiatives including capacity expansions (e.g., 33,870 tons of additional food-grade phosphoric acid; 26,400 tons caustic potash capacity enhancement) suggest growth focus but no immediate volume forecast given in the presentation.
Profitability & Margins
See what Gujarat Alkalies & Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Chlorotoluene Plant (Dahej): Commissioned March 2025, 60% capacity achieved, gradual ramp-up of 30,000 MTPA capacity ongoing.
- Hydrazine Hydrate + Modification Project: 30 TPD, Rs. 425.50 Cr, commissioning planned by Oct 2026.
- Cell Elements Replacement: 590 cells, Rs. 98 Cr, commissioning planned by Dec 2026.
- Caustic Soda Flaker Unit: 200 TPD, Rs. 95 Cr, commissioning planned by Jan 2027.
- HCl Synthesis Unit: 120 TPD, Rs. 351 Cr, commissioning planned by Mar 2027.
- Chlorotoluene Downstream: 140 TPD, Rs. 814 Cr, technical feasibility done, boiler installation planned by May 2028.
- Boilers at Dahej & Vadodara: 2x70 TPH and 2x25 TPH, Rs. 389 Cr, commissioning planned by Nov 2028.
- CSL Revamping and KOH Expansion: 80 TPD, Rs. 808 Cr, commissioning planned by Dec 2028.
- Additional Food Grade Phosphoric Acid Plant: 100 TPD, Rs. 560 Cr, recently completed/ongoing.
2 more points from Gujarat Alkalies & Chemicals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Gujarat Alkalies & Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Gujarat Alkalies & Chemicals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Gujarat Alkalies & Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹1.0K Cr, net loss ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gujarat Alkalies's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Thirumalai Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- Jubilant Agri & Consumer Products Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations: INR 4,510 million, up 13% YoY from INR 3,975 million in Q3 FY25 (Page 20). Key investor presentation takeaways from Jubilant Ag
- Lords Chloro (Q3 FY26)
93.95 crore, up 45% from Rs. Key investor presentation takeaways from Lords Chloro Alkali Ltd's Q3 FY26 investor presentation — and how it ranks against sector
- Chemfab Alka. (Q3 FY26)
Revenue from Operation: ₹62.17 crore, down 21.51% YoY (₹79.21 crore in Q3FY25) . Key investor presentation takeaways from Chemfab Alka.'s Q3 FY26 investor prese
Arthneeti Pro · Annual
Gujarat Alkalies & Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gujarat Alkalies & Chemicals Ltd Q3 FY26 results?
Net External Sales Value for Q3 2025-26 (YTD Dec 25) reported at Rs. EBITDA (Q3 FY 2025-26): ₹393.55 crores - Year-on-year: Up from ₹226.10 crores in Q3 FY 2024-25 - Operating Margin (EBITDA % of Total Income, Q3 FY 2025-26): 11.81% - Compared to 5.80%
What is Gujarat Alkalies & Chemicals Ltd share price analysis?
Gujarat Alkalies & Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 64.8 with a market cap of ₹4,297 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gujarat Alkalies & Chemicals Ltd planning capital expenditure?
Chlorotoluene Plant (Dahej): Commissioned March 2025, 60% capacity achieved, gradual ramp-up of 30,000 MTPA capacity ongoing. - Hydrazine Hydrate + Modification Project: 30 TPD, Rs.
Keep Gujarat Alkalies & Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.